Clinical experience with ceftazidime/avibactam for the treatment of extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in neonates and children

Ozlem Ozgur Gundeslioglu,Zeliha Haytoglu,Hatice Hale Gumus,Faruk Ekinci,Filiz Kibar,Ummuhan Cay,Derya Alabaz,Ferda Ozlu,Ozden Ozgur Horoz,Rıza Dincer Yıldızdas
DOI: https://doi.org/10.1007/s10096-024-04948-y
2024-10-02
European Journal of Clinical Microbiology & Infectious Diseases
Abstract:Klebsiella pneumoniae is a significant cause of healthcare-associated infections, resulting in high morbidity and mortality rates due to limited treatment options. In this study, we aimed to evaluate the treatment outcomes and the safety of Ceftazidime-avibactam in infections caused by extensively drug-resistant or pandrug-resistant Klebsiella pneumoniae in pediatric patients.
infectious diseases,microbiology
What problem does this paper attempt to address?